Gureev AP et al., 2022-09: Russian-authored review of methylene blue's neuroprotective mechanisms, which expressly describes the Parkinson's, Huntington's, traumatic brain injury and other neuro-indications as resting on animal models rather than human trials.
there are premises for its repurposing as a neuroprotective agent based on the efficacy of this compound demonstrated in the models of Alzheimer's, Parkinson's, and Huntington's diseases, traumatic brain injury
abstract
Gureev AP et al., 2022-09: Russian-authored review of methylene blue's neuroprotective mechanisms, which expressly describes the Parkinson's, Huntington's, traumatic brain injury and other neuro-indications as resting on animal models rather than human trials. Study type: narrative review (secondary source). N/A. Country: Russia (Lomonosov Moscow State University group per the affiliation). No dose. Funders/conflicts: not stated in abstract. Confirms the state of the field: for traumatic brain injury, Parkinson's disease and Huntington's disease the evidence is preclinical; this run located no human trial in those indications. Study type: review.
